Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
Stay connected to what’s important in medical research and clinical practice
Subscribe to the most trusted
and influential source of
Already a subscriber? Renew or Sign in
View all specialties
View all topics
View all multimedia
Browse full issue index
Recently Published Articles
Browse recently published
View all learning/CME
Other NEJM Group Learning
This article is available to subscribers. Subscribe now. Already have an account? Sign in
The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for negotiations: how to judge what’s a fair price. Absent well-functioning markets, cost-effectiveness analyses can clarify the value that therapies deliver.
Select an option below:
Are you a member of an institution such as a university or hospital?
Learn more about Institutional Access
Disclosure forms provided by the authors are available at NEJM.org.
This article was published on November 13, 2021, at NEJM.org.
From the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston.
November 18, 2021
N Engl J Med 2021; 385:1923-1924
Print Subscriber? Activate your online access.
Back to top
Create your account for 2 FREE subscriber-only articles each month.